#IPERGAY

A study comparing on-demand and daily PrEP has seen lower side effects with daily use and an overall trend of increased sexual risk-taking.

An analysis of the “on-demand” PrEP study found no new HIV infections among those reporting good adherence and relatively infrequent sex.

The open-label phase of the intercourse-based PrEP dosing study indicates the apparent risk-reduction power of the protocol.

The IPERGAY trial findings of an intermittent dosing schedule of Truvada as pre-exposure prophylaxis (PrEP) among men who have sex with men.

An overview of studies presented at the International AIDS Society Conference in Vancouver, British Columbia.

Non-daily-dosing for PrEP offer high protection against HIV infection through anal sex, while vaginal sex protection is up for debate.

AIDS Healthcare Foundation published an ad criticizing pre-exposure prophylaxis (PrEP) in various gay publications around the country.

Canadian research suggests that rolling out Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) to prevent HIV would save mon...

Daily Truvada as pre-exposure prophylaxis (PrEP) against HIV takes five to seven days to reach top estimated effectiveness among gay men.

Canadian research suggests rolling out Truvada as PrEP to prevent HIV would save money even if cost to treat the virus drops in the future.

New research underscores the great potential of Truvada as pre-exposure prophylaxis for preventing HIV among gay and bisexual men.

A strategy of taking Truvada as PrEP only in the days surrounding intercourse reduced the overall risk of HIV by 86 percent among gay men.

A study of intermittent dosing of Truvada as PrEP among gay and bi men has been stopped due to the intervention’s high efficacy in...

Early results of a study of an intermittent dosing strategy for PrEP have suggested that a high proportion of the participants are...

Oral PrEP is when HIV-negative people take a daily dose of HIV meds to reduce their chance of contracting HIV sexually.